Table 1. Antiviral activity of studied DNA-containing samples.
| Virus titer, TCID50/ml | Reduction of virus titer, % | Reduction of virus titer, n-fold | Specificity factora | |||||
|---|---|---|---|---|---|---|---|---|
| DNA1b | DNA2b | DNA1 | DNA2 | DNA1 | DNA2 | |||
| row | Sample | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| a | DNA | 1,348,963 | 1,148,154 | 15 | 28 | 1 | 1.4 | 1 |
| b | PL-DNA | 147,911 | 794,328 | 90.7 | 50 | 11 | 2.0 | 5 |
| c | DNA + lpfc | 6,310 | 793,349 | 99.6 | 50 | 251 | 2.0 | 130 |
| d | TiO2·PL-DNA | 200 | 630,957 | 99.99 | 60 | 8,000 | 2.5 | 3,160 |
| e | w/o sample | 1,584,893 | ||||||
aratio of the TCID50/ml values for DNA2- and DNA1-containing samples.
bDNA1 and DNA2 are DNA fragments complementary and noncomplementary to viral RNA, respectively.
cLipofectamineTM 2000.